^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
durcabtagene autoleucel (PHE885)
i
Other names: PHE885
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
